Antisense oligonucleotide treatment (ASO)
Phase 2Biologic
Antisense oligonucleotide treatment (ASO) is one of 5 biologic programs targeting Movement Disorder. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
4 competitors in Movement Disorder
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Ingrezza
Neurocrine BiosciencesApproved
Pepcid
KKenvue Brands
Approved
Antisense oligonucleotide treatment (ASO)
MMassachusetts General Hospital
Phase 2
PBR06
UUniversity Hospital, Bordeaux
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital